The combination of BKM120 (PI3K inhibitor) with PRIMA-1 synergistically hampers the growth of thyroid cancer cells in culture and after injection in mice by inhibiting the PI3K/AKT/mTOR and CPSF4/hTERT pathways and reactivating mutant p53 [183]. Here, AKT1 is linked to thyroid gland carcinoma.